Exploring the DNA

Ad5Delta24 (OAd) Bcl-2 gene modulation Drug delivery PNA anti-Bcl-2 PNA gene expression modifiers PNA-adenoviral vector

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
15 Feb 2024
Historique:
received: 21 07 2023
revised: 04 01 2024
accepted: 10 01 2024
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 6 2 2024
Statut: epublish

Résumé

Peptide Nucleic Acids (PNAs) represent a promising tool for gene modulation in anticancer treatment. The uncharged peptidyl backbone and the resistance to chemical and enzymatic degradation make PNAs highly advantageous to form stable hybrid complexes with complementary DNA and RNA strands, providing higher stability than the corresponding natural analogues. Our and other groups' research has successfully shown that tailored PNA sequences can effectively downregulate the expression of human oncogenes using antigene, antisense, or anti-miRNA approaches. Specifically, we identified a seven bases-long PNA sequence, complementary to the longer loop of the main G-quadruplex structure formed by the bcl2midG4 promoter sequence, capable of downregulating the expression of the antiapoptotic Bcl-2 protein and enhancing the anticancer activity of an oncolytic adenovirus. Here, we extended the length of the PNA probe with the aim of including the double-stranded Bcl-2 promoter among the targets of the PNA probe. Our investigation primarily focused on the structural aspects of the resulting DNA

Identifiants

pubmed: 38317891
doi: 10.1016/j.heliyon.2024.e24599
pii: S2405-8440(24)00630-3
pmc: PMC10839560
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e24599

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Andrea P Falanga (AP)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Antonio Lupia (A)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Lorella Tripodi (L)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.
CEINGE-Biotecnologie Avanzate Franco Salvatore S.c.a.r.l., Naples, 80145, Italy.

Carmine M Morgillo (CM)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Federica Moraca (F)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Giovanni N Roviello (GN)

Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale Delle Ricerche, Naples, 80131, Italy.

Bruno Catalanotti (B)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Jussara Amato (J)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Lucio Pastore (L)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.
CEINGE-Biotecnologie Avanzate Franco Salvatore S.c.a.r.l., Naples, 80145, Italy.

Vincenzo Cerullo (V)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.
ImmunoViroTherapy Lab (IVT), Drug Research Program (DRP), Faculty of Pharmacy, University of Helsinki, 00100, Helsinki, Finland.

Stefano D'Errico (S)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Gennaro Piccialli (G)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Giorgia Oliviero (G)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Nicola Borbone (N)

Dipartimento di Farmacia, Università Degli Studi di Napoli Federico II, Naples, 80131, Italy.

Classifications MeSH